01—Abstract
Summary
Summary of the 8-K filed February 26, 2025. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) has successfully completed a significant underwritten public offering of senior notes totaling $4 billiona.
This offering includes four tranches with varying maturities and interest rates: $1.25 billionb in 4.650% notes due 2028, $1 billion in 4.875% notes due 2030, $1 billion in 5.200% notes due 2035, and $750 million in 5.600% notes due 2055. The issuance was registered under an existing Form S-3ASR registration statement and was finalized on February 25, 2025. These new notes are unsecured, unsubordinated obligations of AbbVie, ranking equally with its existing unsecured debt.
The company retains the option to redeem these notes under specific conditions, including at par value after certain dates, with full details outlined in the accompanying indenture. The proceeds from this offering will likely be used to fund corporate activities, potentially including acquisitions, debt refinancing, or general working capital, providing AbbVie with substantial financial flexibility.
02—Key points
Key Highlights
- Completed a $4 billion offering of senior unsecured notes.
- Notes issued include four series with maturities in 2028, 2030, 2035, and 2055.
- Coupon rates range from 4.650% to 5.600%, reflecting market conditions and maturity.
- The offering was registered under AbbVie's existing Form S-3ASR registration statement.
- Notes are governed by a base indenture supplemented by a new supplemental indenture.
- AbbVie has the option to redeem the notes, with specific par call dates and redemption terms.
- The notes rank equally with AbbVie's other unsecured and unsubordinated indebtedness.
03—Questions
Frequently Asked Questions
What was the total amount raised by AbbVie in this offering?
AbbVie raised a total of $4 billion from the offering of its senior notes.
What are the different series of notes issued and their respective interest rates and maturities?
The notes issued are: $1.25 billion of 4.650% senior notes due 2028, $1 billion of 4.875% senior notes due 2030, $1 billion of 5.200% senior notes due 2035, and $750 million of 5.600% senior notes due 2055.
Are these notes secured or unsecured?
These notes are unsecured and unsubordinated obligations of AbbVie, meaning they rank equally with AbbVie's other unsecured and unsubordinated debt.
Does AbbVie have the ability to redeem these notes before maturity?
Yes, AbbVie has the option to redeem the notes, in whole or in part, at specified redemption prices. These options include redemption at par value after certain 'Par Call Dates' which vary by note series, and potentially earlier redemption at a premium prior to these dates.
04—Continue